MyFinsight
Home
About
Contact
cccc: the income statement
Download
Download image
Comprehensive loss
-$32,049K
(-34.82%↓ Y/Y)
Unrealized gain on
marketable securities
$117K
(-86.93%↓ Y/Y)
Net loss
-$32,166K
(-30.41%↓ Y/Y)
Interest and other
income, net
$2,246K
(-37.23%↓ Y/Y)
Loss before income
taxes
-$32,166K
(-30.41%↓ Y/Y)
Total other income,
net
$2,246K
(-37.23%↓ Y/Y)
Biogen Agreement
$2,000K
Roche Agreement
$2,001K
Betta Agreement
$27K
Merck Agreement
$3,842K
MKDGAgreement
$3,360K
Loss from operations
-$34,412K
(-21.84%↓ Y/Y)
Revenue from
collaboration agreements
$11,230K
(-26.90%↓ Y/Y)
Total operating
expenses
$45,642K
(4.67%↑ Y/Y)
Impairment of long-lived
assets
$10,733K
General and
administrative
$8,920K
(-24.20%↓ Y/Y)
Research and development
$25,989K
(-18.37%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)